MedTrace Logo

Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea

NCT06793826 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 713

Last updated 2026-02-18

No results posted yet for this study

Summary

Primary objectives:

To investigate the incidence of adverse events occurred following administration of Hexaxim in infants from 2 months of age under routine clinical practice, as per approved indications

Conditions

  • Hepatitis B
  • Haemophilus Influenzae Type b Immunisation

Interventions

BIOLOGICAL

DTaP-IPV-Hep B-PRP-T combined vaccine

prefilled syringe injection intramuscular

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Clinical Sciences & Operations · Sanofi Pasteur, a Sanofi Company

Eligibility

Min Age
2 Months
Max Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-17
Primary Completion
2026-01-15
Completion
2026-01-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06793826 on ClinicalTrials.gov